Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Scar - Pipeline Review, H2 2017 - Analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) & Molecule Type - Research and Markets

Research and Markets
Posted on: 23 Aug 17

The "Scar - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

The report provides comprehensive information on the therapeutics under development for Scar (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Scar (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Scar and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 2, 13 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Scar (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope of the Report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Scar (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Scar (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Scar (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Scar (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Scar (Dermatology)

Companies Mentioned

  • Abzena Plc
  • Albireo Pharma Inc
  • Altacor Ltd
  • Beech Tree Labs Inc
  • BirchBioMed Inc
  • BLR Bio LLC
  • Clanotech AB
  • Escape Therapeutics Inc
  • FirstString Research Inc
  • Kringle Pharma Inc
  • Pharmaxis Ltd
  • Promore Pharma
  • RXi Pharmaceuticals Corp
  • Synedgen Inc
  • Vascular BioSciences

For more information about this report visit https://www.researchandmarkets.com/research/mlhqzz/scar_pipeline

View source version on businesswire.com: http://www.businesswire.com/news/home/20170823005974/en/

Business Wire
www.businesswire.com

Last updated on: 23/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.